// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























41730 Abstracts

Concurrent boost technique in prostate IMRT and accuracy of planning target volume (PTV) at the periphery.

Santhanam Sundar - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Hereditary cancer syndromes and prostate cancer development among African American men: The importance of complete family cancer history.

Elias Obeid - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

MMP-7 a potential biomarker of invasive cervix cancer: A prospective pilot study.

David Mysona - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Stage IA2 cervical cancer: Long-term outcomes with less radical as opposed to more radical surgical management.

Jill Tseng - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Neoadjuvant chemotherapy in cervical cancer patients: a single institution experience.

Matilde Destefanis - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Ifosfamide

An international multicenter phase III study of chemoradiotherapy versus chemoradiotherapy plus hyperthermia for locally advanced cervical cancer.

Baukje Flameling - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cisplatin

Study of HPV infection in tissues of tumor and lymph nodes of patients with cervical cancer.

Galina Andreevna Nerodo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Hormonal balance in preserved ovaries after combined treatment for cervical cancer.

Polina Kruze - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Cancers attributable to infectious agents in Nigeria: 2012-2014.

Michael Kolawole Odutola - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

ARID1A alterations in gynecological cancers as a therapeutic opportunity.

Laura Gonzalez-Malerva - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A phase I dose-escalation study of BGB-290, a novel PARP1/2 selective inhibitor in patients with advanced solid tumors.

Jason D. Lickliter - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

BGB-290

Evaluation of genomic alterations in primary small cell carcinoma of the ovary (SCCO).

George Yaghmour - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Efficacy and safety of adjuvant intraperitoneal chemotherapy in carcinoma ovary: A prospective observational study.

Varun Goel - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Carboplatin

Identification of druggable targets in high-grade epithelial ovarian cancer (EOC) using next generation sequencing (NGS)based molecular diagnostic.

Jean-Louis Merlin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Impact of obesity on survival and recurrence of high grade serous carcinoma of the ovary.

Carolina Ibanez - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Evaluation of centrosome clustering protein KIFC1 as a potential prognostic biomarker in serous ovarian adenocarcinomas.

Karuna Mittal - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

T-LAK cell-originated protein kinase (TOPK) as a prognostic factor and a potential therapeutic target in ovarian cancer.

Yuji Ikeda - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

OTS964

Toxicity related to first line, platinum-based chemotherapy in BRCA1-associated epithelial ovarian cancer: Is DNA repairing impairment associated with more adverse events?

Agnieszka Badora-Rybicka - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Paclitaxel

Safety and efficacy of new techniques of radiotherapy in oligometastatic recurrence ovarian cancer ( ROC) patients with BRCA 1/2 mutation. A monoistitutional experience.

Giuseppa Scandurra - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Carboplatin

Prospective comparison of different methods of identifying Lynch Syndrome (LS) associated endometrial cancer (EC) and prognostic factor (PF) impact.

Ignacio Romero - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Copyright © 2026. QuantiNova All rights reserved